CO6341637A2 - \\\\\\\"composiciones y metodos novedosos\\\\\\\" - Google Patents

\\\\\\\"composiciones y metodos novedosos\\\\\\\"

Info

Publication number
CO6341637A2
CO6341637A2 CO11009231A CO11009231A CO6341637A2 CO 6341637 A2 CO6341637 A2 CO 6341637A2 CO 11009231 A CO11009231 A CO 11009231A CO 11009231 A CO11009231 A CO 11009231A CO 6341637 A2 CO6341637 A2 CO 6341637A2
Authority
CO
Colombia
Prior art keywords
methods
rv3616c
new compositions
protein sequence
prevention
Prior art date
Application number
CO11009231A
Other languages
English (en)
Spanish (es)
Inventor
James E Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biolog Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biolog Sa
Publication of CO6341637A2 publication Critical patent/CO6341637A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CO11009231A 2008-07-25 2011-01-27 \\\\\\\"composiciones y metodos novedosos\\\\\\\" CO6341637A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
CO6341637A2 true CO6341637A2 (es) 2011-11-21

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11009231A CO6341637A2 (es) 2008-07-25 2011-01-27 \\\\\\\"composiciones y metodos novedosos\\\\\\\"

Country Status (24)

Country Link
US (2) US20110117119A1 (enExample)
EP (1) EP2315773B1 (enExample)
JP (1) JP5873332B2 (enExample)
KR (1) KR20110044883A (enExample)
CN (1) CN102164952B (enExample)
AU (1) AU2009273130B2 (enExample)
BR (1) BRPI0916703A2 (enExample)
CA (1) CA2731499C (enExample)
CO (1) CO6341637A2 (enExample)
CY (1) CY1118200T1 (enExample)
DK (1) DK2315773T3 (enExample)
EA (1) EA024826B1 (enExample)
ES (1) ES2602430T3 (enExample)
HR (1) HRP20161458T1 (enExample)
HU (1) HUE031044T2 (enExample)
IL (1) IL210559A0 (enExample)
LT (1) LT2315773T (enExample)
MX (1) MX2011000983A (enExample)
PL (1) PL2315773T3 (enExample)
PT (1) PT2315773T (enExample)
SG (1) SG192456A1 (enExample)
SI (1) SI2315773T1 (enExample)
UA (1) UA107330C2 (enExample)
WO (1) WO2010010177A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1350546A (zh) * 1998-11-04 2002-05-22 Isis创新有限公司 结核诊断测验
EP2315597B1 (en) 2008-07-25 2017-08-23 GlaxoSmithKline Biologicals S.A. Novel compositions and methods
WO2010010179A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
CN102413837B (zh) 2009-04-24 2015-11-25 国立血清研究所 预防再激活的结核病tb疫苗
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
CN105765592B (zh) 2013-09-27 2019-12-17 科德克希思公司 用于酶变体的自动筛选的方法、装置和系统
JP6309086B2 (ja) * 2013-09-27 2018-04-11 コデクシス, インコーポレイテッド 構造ベース予測モデリング
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999051748A2 (en) * 1998-04-07 1999-10-14 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
AU6867801A (en) * 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
CA2433236C (en) * 2001-01-08 2016-10-04 Isis Innovation Limited Assay to determine efficacy of treatment for m. tuberculosis infection
CN1277843C (zh) * 2001-02-22 2006-10-04 巴斯德研究院 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
PL2457926T3 (pl) 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
AU2006261445B2 (en) * 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EP2368568A1 (en) * 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
CN102413837B (zh) * 2009-04-24 2015-11-25 国立血清研究所 预防再激活的结核病tb疫苗
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy

Also Published As

Publication number Publication date
EA024826B1 (ru) 2016-10-31
AU2009273130B2 (en) 2014-10-16
CY1118200T1 (el) 2017-06-28
AU2009273130A1 (en) 2010-01-28
HUE031044T2 (en) 2017-06-28
HRP20161458T1 (hr) 2016-12-16
WO2010010177A1 (en) 2010-01-28
CN102164952B (zh) 2016-05-25
US20140178423A1 (en) 2014-06-26
PL2315773T3 (pl) 2017-07-31
KR20110044883A (ko) 2011-05-02
UA107330C2 (uk) 2014-12-25
US20110117119A1 (en) 2011-05-19
CN102164952A (zh) 2011-08-24
BRPI0916703A2 (pt) 2019-12-24
US9795663B2 (en) 2017-10-24
LT2315773T (lt) 2016-11-10
CA2731499C (en) 2017-01-10
MX2011000983A (es) 2011-03-02
PT2315773T (pt) 2016-11-23
SI2315773T1 (sl) 2016-12-30
JP2011528895A (ja) 2011-12-01
EA201100072A1 (ru) 2011-10-31
JP5873332B2 (ja) 2016-03-01
IL210559A0 (en) 2011-03-31
EP2315773B1 (en) 2016-08-24
EP2315773A1 (en) 2011-05-04
DK2315773T3 (en) 2016-12-12
ES2602430T3 (es) 2017-02-21
CA2731499A1 (en) 2010-01-28
SG192456A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
CO6400198A2 (es) Composiciones y metodos novedosos
AR125326A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
BR112014007675A2 (pt) tratamento de doença articular degenerativa
AR084285A1 (es) Composiciones inmunogenicas
ECSP077261A (es) Composición de anticuerpo her2
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
AR080914A1 (es) Proteinas de union al beta-amiloide
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
ATE404225T1 (de) Radiofluorierte peptide
BR112012015188A2 (pt) "composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese"
CL2010001569A1 (es) Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro.
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden

Legal Events

Date Code Title Description
FC Application refused